Drug Notebook

FDA Alerts

    Bone Mineral Density
  • Use of parenteral medroxyprogesterone preparations (i.e., Depo-Provera® Contraceptive, depo-subQ provera 104®, or medroxyprogesterone acetate contraceptive injection) may result in loss of bone mineral density (BMD). Bone loss is greater with increasing duration of therapy and may not be completely reversible.
  • Not known whether use of these parenteral preparations in young women (e.g., during adolescence, early adulthood) will reduce peak bone mass and increase risk of osteoporotic fractures later in life. Loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion.
  • Use parenteral medroxyprogesterone for long-term contraception (e.g., >2 years) only if other contraceptive methods are inadequate.

Media Gallery
Drug Info Tools
Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
Licensed from
medroxyPROGESTERone
Page: 1 2 Next >
(me DROX ee proe JES ter one)

What is the most important information I should know about medroxyprogesterone?

You should not use this medication if you are pregnant, or if you have liver disease, a hormone-related cancer such as breast or uterine cancer, a history of stroke or blood clot, or abnormal vaginal bleeding that has not been checked by a doctor. Medroxyprogesterone will not prevent heart disease, breast cancer, or dementia, and may actually increase the risk of developing these conditions in post-menopausal women. Medroxyprogesterone may also increase the risk of uterine or ovarian cancer in some women. Long-term treatment with estrogens and progestins (such as medroxyprogesterone) may also increase your risk of heart attack, blood clot, or stroke.

Talk to your doctor about your specific risks and benefits of taking this medication, especially if you smoke or are overweight. Your doctor should check your progress on a regular basis (every 3 to 6 months) to determine whether you should continue this treatment.

What is medroxyprogesterone?

Medroxyprogesterone is a progestin (a form of progesterone), a female hormone that helps regulate ovulation (the release of an egg from an ovary) and menstrual periods.

Medroxyprogesterone is used to treat conditions such as absent or irregular menstrual periods, or abnormal uterine bleeding. Medroxyprogesterone is also used to decrease the risk of endometrial hyperplasia (a condition that may lead to uterine cancer) while taking estrogens.

Medroxyprogesterone is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy.

Medroxyprogesterone may also be used for other purposes not listed in this medication guide.

What should I discuss with my healthcare provider before taking medroxyprogesterone?

FDA pregnancy category X. Medroxyprogesterone can cause birth defects. Do not use if this medication you are pregnant. Tell your doctor right away if you become pregnant during treatment. You should not use this medication if you are allergic to medroxyprogesterone, or if you have:
  • abnormal vaginal bleeding that has not been diagnosed;

  • a hormone-related cancer such as breast or uterine cancer;

  • liver disease; or

  • a history of stroke or blood clot.

If you have certain conditions, you may need a dose adjustment or special tests to safely take this medication. Before using medroxyprogesterone, tell your doctor if you have:

Medroxyprogesterone can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Medroxyprogesterone will not prevent heart disease, breast cancer, or dementia, and may actually increase the risk of developing these conditions in post-menopausal women. Medroxyprogesterone may also increase the risk of uterine or ovarian cancer in some women. Long-term treatment with estrogens and progestins (such as medroxyprogesterone) may also increase your risk of heart attack, blood clot, or stroke.

Talk to your doctor about your specific risks and benefits of taking this medication, especially if you smoke or are overweight. Your doctor should check your progress on a regular basis (every 3 to 6 months) to determine whether you should continue this treatment.

Page: 1 2 Next >
Advertisement
Back to Top